RESUMEN

Gene transfer to create tumour epitope-specific cytolytic T cells for adoptive immunotherapy of cancer remains an area of active inquiry. When the Mart-127-35 -specific DMF5 T-cell receptor (TCR) is transferred into peripheral human CD4(+) T cells, the reprogrammed cells exhibit a T helper type 1 (Th1) phenotype with significant multifactorial effector capabilities. The T-bet transcription factor plays an important role in determination of the Th1 differentiation pathway. To gain a deeper understanding of how T-bet controls the outcome of human T-cell reprogramming by gene transfer, we developed a system for examining the effects of short hairpin RNA-mediated T-bet gene knockdown in sorted cell populations uniformly expressing the knockdown construct. In this system, using activated peripheral human CD4(+)  CD25(-) and CD8(+) T cells, T-bet knockdown led to attenuation of the interferon-γ response to both antigen-specific and non-specific TCR stimulation. The interleukin-2 (IL-2) antigen-specific response was not attenuated by T-bet knockdown. Also, in TCR-reprogrammed CD8(+) cells, the cytolytic effector response was attenuated by T-bet knockdown. T-bet knockdown did not cause redirection into a Th2 differentiation pathway, and no increased IL-4, IL-10, or IL-17 response was detected in this system. These results indicate that T-bet expression is required for maintenance of the CD4(+)  CD25(-) and CD8(+) effector phenotypes in TCR-reprogrammed human T cells. They also suggest that the activation protocol necessary for transduction with retrovectors and lentivectors may commit the reprogrammed cells to the Th1 phenotype, which cannot be altered by T-bet knockdown but that there is, nevertheless, a continuous requirement of T-bet expression for interferon-γ gene activation.

Asunto(s)

Linfocitos T CD8-positivos/inmunología , Reprogramación Celular , Ingeniería de Proteínas , Receptores de Antígenos , Proteínas de Dominio T Box , Células TH1/inmunología , Línea Celular , Citocinas/genética , Citocinas/inmunología , Técnicas de Silenciamiento del Gen , Humanos , Receptores de Antígenos/genética , Receptores de Antígenos/inmunología , Proteínas de Dominio T Box/genética , Proteínas de Dominio T Box/inmunología

RESUMEN

There is enormous interest in studying HIV pathogenesis for improving the treatment of patients with HIV infection. HIV infection has become one of the best-studied systems for understanding how a virus can hijack a cell. To help facilitate discovery, we previously built HIVToolbox, a web system for visual data mining. The original HIVToolbox integrated information for HIV protein sequence, structure, functional sites, and sequence conservation. This web system has been used for almost 40,000 searches. We report improvements to HIVToolbox including new functions and workflows, data updates, and updates for ease of use. HIVToolbox2, is an improvement over HIVToolbox with new functions. HIVToolbox2 has new functionalities focused on HIV pathogenesis including drug-binding sites, drug-resistance mutations, and immune epitopes. The integrated, interactive view enables visual mining to generate hypotheses that are not readily revealed by other approaches. Most HIV proteins form multimers, and there are posttranslational modification and protein-protein interaction sites at many of these multimerization interfaces. Analysis of protease drug binding sites reveals an anatomy of drug resistance with different types of drug-resistance mutations regionally localized on the surface of protease. Some of these drug-resistance mutations have a high prevalence in specific HIV-1 M subtypes. Finally, consolidation of Tat functional sites reveals a hotspot region where there appear to be 30 interactions or posttranslational modifications. A cursory analysis with HIVToolbox2 has helped to identify several global patterns for HIV proteins. An initial analysis with this tool identifies homomultimerization of almost all HIV proteins, functional sites that overlap with multimerization sites, a global drug resistance anatomy for HIV protease, and specific distributions of some DRMs in specific HIV M subtypes. HIVToolbox2 is an open-access web application available at [http://hivtoolbox2.bio-toolkit.com].

Asunto(s)

Fármacos Anti-VIH/química , Farmacorresistencia Viral/genética , VIH/efectos de los fármacos , Proteínas del Virus de la Inmunodeficiencia Humana/química , Mutación , Programas Informáticos , Secuencia de Aminoácidos , Sitios de Unión/genética , Análisis Mutacional de ADN , Bases de Datos Genéticas , VIH/genética , VIH/metabolismo , Proteínas del Virus de la Inmunodeficiencia Humana/efectos de los fármacos , Proteínas del Virus de la Inmunodeficiencia Humana/genética , Proteínas del Virus de la Inmunodeficiencia Humana/metabolismo , Humanos , Internet , Conformación Proteica , Multimerización de Proteína , Procesamiento Proteico-Postraduccional , Análisis de Secuencia de Proteína

RESUMEN

MHC class I-restricted human melanoma epitope MART-1(27-35) specific TCR-engineered CD4+CD25- T cells synthesize Th1 type cytokines and exhibit cytolytic effector function upon cognate stimulation. A detailed characterization of such TCR-engineered CD4+CD25- T cells now reveals that they are multifunctional. For example, they undergo multiple rounds of division, synthesize cytokines (IFN-gamma, TNF-alpha, IL-2, and MIP1ss), lyse target cells, and "help" the expansion of the MART-1(27-35) specific CD8+ T cells when stimulated by the MART-1(27-35) peptide pulsed DC. Multiparametric analyses reveal that a single TCR-engineered CD4+ T cell can perform as many as five different functions. Nearly 100% MART-1(27-35) specific TCR expressing CD4+ T cells can be generated through retroviral vector-based transduction and one round of in vitro stimulation by the peptide pulsed DC. MHC class I-restricted tumor epitope specific TCR transduced CD4+ T cells, therefore, could be useful in immunotherapeutic strategies for melanoma or other human malignancies.

Asunto(s)

Linfocitos T CD4-Positivos/inmunología , Epítopos/inmunología , Proteínas de Neoplasias/inmunología , Linfocitos T CD4-Positivos/clasificación , Linfocitos T CD4-Positivos/citología , Linfocitos T CD8-positivos/citología , Linfocitos T CD8-positivos/inmunología , Línea Celular , Línea Celular Tumoral , Proliferación Celular , Ingeniería Genética , Antígenos de Histocompatibilidad Clase I/metabolismo , Humanos , Inmunoterapia Activa , Inmunoterapia Adoptiva , Técnicas In Vitro , Activación de Linfocitos , Melanoma/inmunología , Melanoma/terapia , Receptores de Antígenos de Linfocitos T/genética , Linfocitos T Colaboradores-Inductores/clasificación , Linfocitos T Colaboradores-Inductores/citología , Linfocitos T Colaboradores-Inductores/inmunología , Transducción Genética

RESUMEN

Cytolytic T cell-centric active specific and adoptive immunotherapeutic approaches might benefit from the simultaneous engagement of CD4(+) T cells. Considering the difficulties in simultaneously engaging CD4(+) and CD8(+) T cells in tumor immunotherapy, especially in an Ag-specific manner, redirecting CD4(+) T cells to MHC class I-restricted epitopes through engineered expression of MHC class I-restricted epitope-specific TCRs in CD4(+) T cells has emerged as a strategic consideration. Such TCR-engineered CD4(+) T cells have been shown to be capable of synthesizing cytokines as well as lysing target cells. We have conducted a critical examination of functional characteristics of CD4(+) T cells engineered to express the alpha- and beta-chains of a high functional avidity TCR specific for the melanoma epitope, MART-1(27-35), as a prototypic human tumor Ag system. We found that unpolarized CD4(+)CD25(-) T cells engineered to express the MART-1(27-35) TCR selectively synthesize Th1 cytokines and exhibit a potent Ag-specific lytic granule exocytosis-mediated cytolytic effector function of comparable efficacy to that of CD8(+) CTL. Such TCR engineered CD4(+) T cells, therefore, might be useful in clinical immunotherapy.

Asunto(s)

Linfocitos T CD4-Positivos/inmunología , Citocinas/biosíntesis , Citotoxicidad Inmunológica , Epítopos/inmunología , Antígenos de Histocompatibilidad Clase I/inmunología , Melanoma/inmunología , Proteínas de Neoplasias/inmunología , Receptores de Antígenos de Linfocitos T/inmunología , Células TH1/inmunología , Linfocitos T CD4-Positivos/metabolismo , Linfocitos T CD8-positivos/inmunología , Linfocitos T CD8-positivos/metabolismo , Línea Celular Tumoral , Citocinas/inmunología , Epítopos/metabolismo , Vectores Genéticos , Humanos , Melanoma/metabolismo , Proteínas de Neoplasias/metabolismo , Receptores de Antígenos de Linfocitos T/metabolismo , Células TH1/metabolismo , Transducción Genética , Transgenes

RESUMEN

Activation-induced cell death (AICD) of T cells can be an impediment towards achieving a robust and long-lived cytolytic T lymphocyte (CTL) response from active specific immunization or after adoptive cell transfer in cancer immunotherapy. The mechanism of AICD in primary CTL, however, remains poorly understood. It is widely believed that AICD is driven by signals from death receptors (DR) and that the cell death takes place in a caspase-dependent manner, although it has been shown that AICD of T cells can be induced by internal triggers and that death takes place in a caspase-independent manner. We show here that AICD in human melanoma epitope-specific primary CTL involves selective mitochondrio-nuclear translocation of the apoptosis inducing factor (AIF) without cytochrome c release, caspase-3 and caspase-8 activation, and results from large-scale DNA fragmentation. The c-jun-N terminal kinase (JNK) inhibitor, SP600125, blocks the mitochondrio-nuclear translocation of AIF and prevents AICD in these CTL. These findings suggest that the AICD in human melanoma epitope specific primary CTL is mediated by mitochondrial AIF release and JNK is involved in regulation of this death process.

Asunto(s)

Factor Inductor de la Apoptosis/fisiología , Apoptosis/inmunología , Activación de Linfocitos/inmunología , Melanoma/inmunología , Melanoma/metabolismo , Linfocitos T Citotóxicos/metabolismo , Antracenos/farmacología , Apoptosis/efectos de los fármacos , Humanos , Células Jurkat , Melanoma/patología , Linfocitos T Citotóxicos/efectos de los fármacos , Linfocitos T Citotóxicos/inmunología , Células Tumorales Cultivadas

RESUMEN

The in vivo failure of implantable glucose sensors is thought to be largely the result of inflammation and fibrosis-induced vessel regression at sites of sensor implantation. To determine whether increased vessel density at sites of sensor implantation would enhance sensor function, cells genetically engineered to over-express the angiogenic factor (AF) vascular endothelial cell growth factor (VEGF) were incorporated into an ex ova chicken embryo chorioallantoic membrane (CAM)-glucose sensor model. The VEGF-producing cells were delivered to sites of glucose sensor implantation on the CAM using a tissue-interactive fibrin bio-hydrogel as a cell support and activation matrix. This VEGF-cell-fibrin system induced significant neovascularization surrounding the implanted sensor, and significantly enhanced the glucose sensor function in vivo. This model system, for the first time, provides the "proof of principle" that increasing vessel density at the sites of implantation can enhance glucose sensor function in vivo, and demonstrates the potential of gene transfer and tissue interactive fibrin bio-hydrogels in the development of successful implants.

Asunto(s)

Técnicas Biosensibles/métodos , Glucemia/análisis , Membrana Corioalantoides/trasplante , Sistemas de Liberación de Medicamentos/métodos , Reacción a Cuerpo Extraño/prevención & control , Neovascularización Fisiológica/efectos de los fármacos , Factor A de Crecimiento Endotelial Vascular/administración & dosificación , Animales , Técnicas Biosensibles/instrumentación , Embrión de Pollo , Pollos , Membrana Corioalantoides/metabolismo , Sistemas de Liberación de Medicamentos/instrumentación , Implantes de Medicamentos/química , Reacción a Cuerpo Extraño/patología , Técnicas de Transferencia de Gen , Factor A de Crecimiento Endotelial Vascular/genética

RESUMEN

Dendritic cells (DC) play critical roles in generating an immune response and in inducing tolerance. Diverse microenvironmental factors can 'polarize' DC toward an immunogenic or non-immunogenic phenotype. Among the various microenvironmental factors, interleukin-10 (IL-10) exhibits a potent immunosuppressive effect on antigen-presenting cells (APC). Here, we show that monocyte-derived DC generated in the presence of IL-10 exhibit a profound down-regulation of many genes that are associated with immune activation and show that the IL-10-grown DC are poor stimulators of CD8(+) T cells in a strictly autologous and major histocompatibility complex (MHC) class I-restricted melanoma antigen recognized by T cells (MART-1) epitope presentation system. However, these IL-10-grown DC can efficiently activate the epitope-specific CD8(+) T cells when they are made to present the epitope following transduction with an adenoviral vector expressing the MART-1 antigen. In addition, we show that the MART-1 protein colocalizes with the MHC class I protein, equally well, in the iDC and in the DC cultured in presence of IL-10 when both DC types are infected with the viral vector. We also show that the vector transduced DC present the MART-1(27-35) epitope for a sustained period compared to the peptide pulsed DC. These data suggest that although DCs generated in the presence of IL-10 tend to be non-immunogenic, they are capable of processing and presenting an antigen when the antigen is synthesized within the DC.

Asunto(s)

Presentación de Antígeno/inmunología , Antígenos de Neoplasias/inmunología , Células Dendríticas/inmunología , Interleucina-10/inmunología , Proteínas de Neoplasias/inmunología , Adenoviridae/genética , Linfocitos T CD8-positivos/inmunología , Citotoxicidad Inmunológica/inmunología , Vectores Genéticos , Humanos , Inmunofenotipificación , Interferón gamma/biosíntesis , Interleucina-10/genética , Activación de Linfocitos/inmunología , Antígeno MART-1 , Melanoma/inmunología , Proteínas de Neoplasias/genética , Transducción Genética

RESUMEN

Activation-induced cell death (AICD) as well as programmed cell death (PCD) serve to control the expansion of activated T cells to limit untoward side effects of continued effector responses by T cells and to maintain homeostasis. AICD of T cells in tumor immunotherapy can be counterproductive particularly if the activated T cells undergo apoptotic death after the very first secondary encounter of the specific epitope. We examined the extent to which tumor epitope-specific CTLs that are activated and expanded in an in vitro-matured dendritic cell-based primary stimulation protocol undergo AICD following their first secondary encounter of the cognate epitope. Using the MART-1(27-35) epitope as a prototype vaccine epitope, we also examined whether these CTLs could be rescued from AICD. Our results demonstrate that a substantial fraction of MART-1(27-35) epitope-specific primary CTLs undergo AICD upon the very first secondary encounter of the cognate epitope. The AICD in these CTLs is neither caspase dependent nor is it triggered by the extrinsic death signaling pathways (Fas, TNFR, etc.). These CTLs, interestingly, could be rescued from AICD by the JNK inhibitor, SP600125. We also found that SP600125 interferes with their IFN-gamma response but does not block their cytolytic function. The rescued CTLs, however, regain their capacity to synthesize IFN-gamma if continued in culture without the inhibitor. These observations have implications in tumor immunotherapy and in further studies for regulation of AICD in CTLs.

Asunto(s)

Antracenos/farmacología , Epítopos de Linfocito T/inmunología , Inmunoterapia Adoptiva , Proteínas Quinasas JNK Activadas por Mitógenos/antagonistas & inhibidores , Activación de Linfocitos/inmunología , Melanoma/terapia , Linfocitos T Citotóxicos/citología , Linfocitos T Citotóxicos/inmunología , Presentación de Antígeno , Muerte Celular/efectos de los fármacos , Muerte Celular/inmunología , Línea Celular Tumoral , Células Cultivadas , Técnicas de Cocultivo , Citotoxicidad Inmunológica/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Epítopos/inmunología , Epítopos de Linfocito T/metabolismo , Humanos , Epítopos Inmunodominantes/inmunología , Inmunoterapia Adoptiva/métodos , Interferón gamma/antagonistas & inhibidores , Interferón gamma/biosíntesis , Interleucina-15/farmacología , Activación de Linfocitos/efectos de los fármacos , Melanoma/enzimología , Melanoma/inmunología , Proteínas de Neoplasias/inmunología , Linfocitos T Citotóxicos/enzimología

RESUMEN

Dendritic cells (DC) capture antigens from apoptotic and/or necrotic tumor cells and cross-present them to T cells, and various ways of delivering tumor antigens to DC in vitro and in vivo are being pursued. Since fusions of antigenic proteins with the HSV integument protein VP22 are capable of intercellular trafficking, this approach has been exploited for delivery of antigens to antigen-presenting cells. Adenoviral vectors were used to express the tumor-associated-but-self-antigen MART-1 fused to HSV VP22 in MART-1-negative A375 melanoma cells and in DC. When expressed in A375 cells and allowed to spread to DC across a transwell barrier, the VP22-MART-1 fusion protein localized to both early and late endosomal structures of the DC. The DC loaded with the VP22-MART-1 fusion by intercellular trafficking efficiently presented the MART-1(27-35) epitope to MART-1(27-35)-specific CTL. Furthermore, transloaded DC were capable of expanding the population of MART-1(27-35)-specific CTL. Thus, a tumor antigen acquired by intercellular trafficking can be cross-presented by DC. This experimental approach should therefore be useful not only for studying the mechanism of cross-presentation but also for vaccine development.

Asunto(s)

Antígenos de Neoplasias/inmunología , Reactividad Cruzada/inmunología , Células Dendríticas/inmunología , Proteínas de Neoplasias/metabolismo , Transporte de Proteínas/fisiología , Proteínas Estructurales Virales/metabolismo , Adenoviridae/genética , Animales , Presentación de Antígeno/inmunología , Vacunas contra el Cáncer , Células Cultivadas , Citometría de Flujo , Técnica del Anticuerpo Fluorescente , Vectores Genéticos , Humanos , Activación de Linfocitos , Antígeno MART-1 , Proteínas de Neoplasias/inmunología , Proteínas Recombinantes de Fusión/inmunología , Proteínas Recombinantes de Fusión/metabolismo , Simplexvirus/inmunología , Linfocitos T Citotóxicos/inmunología , Proteínas Estructurales Virales/inmunología

RESUMEN

One of the major obstacles in developing rationale strategies to control inflammation and fibrosis surrounding implants is the lack of a simple and inexpensive in vivo model to screen tissue reactions to various biomaterials and implants. To begin to fill this gap, we have developed an ex ova model of the chick embryo chorioallantoic membrane (CAM) for testing of tissue reaction to biomaterials and implants. For these studies, we evaluated tissue reactions (inflammation and fibrosis) to two commonly used biomaterials (nylon and silastic) grossly and histologically in the ex ova CAM. Nylon mesh was incorporated within the CAM tissue 4 days postplacement. After 8 days postplacement, the nylon mesh was totally incorporated into the CAM. Histologically, little or no inflammation was seen associated with the incorporated nylon mesh at any time point. In the case of silastic tubing, significant incorporation of the CAM was seen grossly by 1-2 days postplacement. Incorporation of the tubing continued at day 8 postplacement of the silastic tubing, with ingrowth of the CAM into the lumen of the tubing. Histological evaluation of CAMs indicated that no significant tissue reactions (inflammation or fibrosis) occurred in the CAM tissue surrounding the silastic tubing or in the CAM tissue and vasculature that had grown into the silastic tubing. To our knowledge, this report represents the first investigation of the usage of the ex ova CAM model, a shell-less chick embryo model (ex ova), as an in vivo model to test the tissue reactions to biomaterials and implants.

Asunto(s)

Alantoides/efectos de los fármacos , Materiales Biocompatibles/farmacología , Corion/efectos de los fármacos , Ensayo de Materiales/métodos , Prótesis e Implantes/normas , Animales , Materiales Biocompatibles/normas , Embrión de Pollo , Dimetilpolisiloxanos/farmacología , Técnicas Histológicas , Modelos Animales , Neovascularización Fisiológica/efectos de los fármacos , Nylons/farmacología , Siliconas/farmacología , Factores de Tiempo

RESUMEN

Dendritic cell (DC)-based immunization in cancer has proven to be a promising approach. However, just as DCs are crucial accessory cells in generating immune responses, they also seem to participate in tolerance induction, especially against peripheral "self" antigens. The bulk of the evidence that DCs present peripheral self antigens to induce tolerance has, however, come mostly from studies in transgenic animal models. A tolerogenic function of DCs for peripheral self antigens in a human model has not been critically examined. In this study using the Melan-A/MART-1(27-35) peptide as a model for self but melanoma-associated antigen-against which human hosts often harbor CD8(+) CTL precursors with high frequencies-we confirm that although immature dendritic cells (iDCs) are inefficient antigen presenting cells (APCs), fully activated DCs efficiently activate melanoma epitope-specific CD8(+) CTL precursors, in vitro. We, however, show that in a direct epitope presentation schema, iDCs neither delete nor anergize epitope-specific CD8(+) T cells in primary or secondary stimulation. Interestingly, iDCs and activated DCs can delete a large fraction of the epitope-specific CTLs on tertiary stimulation. The deletion is induced in an epitope-specific manner and through apoptosis. These observations, therefore, have implications on the DC-based cancer vaccine designs and are relevant in the inquiry into the role of DCs on tolerance induction.

Asunto(s)

Células Dendríticas/inmunología , Epítopos de Linfocito T/inmunología , Melanoma/inmunología , Linfocitos T Citotóxicos/inmunología , Autoantígenos/inmunología , Epítopos/inmunología , Humanos , Tolerancia Inmunológica/inmunología , Activación de Linfocitos/inmunología , Proteínas de Neoplasias/inmunología